|
| Wednesday, July 1, 2020 |
|
|
華領醫藥宣佈Dorzagliatin與二甲雙胍聯合用藥III期註冊臨床研究24週核心研究取得正面結果 |
| 華領醫藥今天宣佈其在中國開展的全球首創新藥葡萄糖激酶激活劑dorzagliatin與二甲雙胍（2型糖尿病全球一線用藥）聯合用藥III期註冊臨床研究（HMM0302）的24週核心研究的正面結果。 more info >> |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
|
华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED研究（HMM0301） |
| 华领医药（“公司”，香港联交所股份代号：2552.HK），一家针对全球糖尿病患者尚未满足的临床需求研发全球原创新药的生物技术公司，今天宣布了dorzagliatin的首个III期临床试验，SEED（也称为HMM0301）的结果。 more info >> |
|
|
華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED研究（HMM0301） |
| 華領醫藥（“公司”，香港聯交所股份代號：2552.HK），一家針對全球糖尿病患者尚未滿足的臨床需求研發全球原創新藥的生物技術公司，今天宣佈了dorzagliatin的首個III期臨床試驗，SEED（也稱為HMM0301）的結果。 more info >> |
|
| Monday, April 27, 2020 |
|
|
华领医药宣布Dorzagliatin与恩格列净（一种SGLT-2抑制剂）联合用药临床研究的成功结果 |
| 华领医药技术（上海）有限公司（以下简称「华领医药」，香港联交所股份代号：2552.HK）宣布临床研究HMM0112的成功结果。 more info >> |
|
|
華領醫藥宣佈Dorzagliatin與恩格列淨（一種SGLT-2抑制劑）聯合用藥臨床研究的成功結果 |
| 華領醫藥技術（上海）有限公司（以下簡稱「華領醫藥」，香港聯交所股份代號：2552.HK）宣佈臨床研究HMM0112的成功結果。 more info >> |
|
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
| Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
| Monday, March 16, 2020 |
|
|
华领医药公布2019年全年业绩 |
| 华领医药（「公司」，香港联交所股份代号：2552），一家针对糖尿病临床需求的全球首创新药研发公司，宣布公司及其附属公司截至2019年12月31日止经审核的全年业绩。 more info >> |
|
|
Hua Medicine Announces 2019 Annual Results |
| Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. more info >> |
|
|
|
|
